

- concentrations. *Nat Microbiol.* 2022;7:1951–5. <https://doi.org/10.1038/s41564-022-01269-8>
4. Hughes C, McCollum A, Pukuta E, Karhemere S, Nguete B, Lushima RS, et al. Ocular complications associated with acute monkeypox virus infection, DRC. *Int J Infect Dis.* 2014;21:276–7. <https://doi.org/10.1016/j.ijid.2014.03.994>
  5. Iñigo Martínez J, Gil Montalbán E, Jiménez Bueno S, Martín Martínez F, Nieto Juliá A, Sánchez Díaz J, et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022. *Euro Surveill.* 2022;27:2200471. <https://doi.org/10.2807/1560-7917.ES.2022.27.27.2200471>
  6. Vusirikala A, Charles H, Balasegaram S, Macdonald N, Kumar D, Barker-Burnside C, et al. Epidemiology of early monkeypox virus transmission in sexual networks of gay and bisexual men, England, 2022. *Emerg Infect Dis.* 2022;28:2082–6. <https://doi.org/10.3201/eid2810.220960>
  7. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al.; SHARE-net Clinical Group. Monkeypox virus infection in humans across 16 countries – April–June 2022. *N Engl J Med.* 2022;387:679–91. <https://doi.org/10.1056/NEJMoa2207323>
  8. Lapa D, Carletti F, Mazzotta V, Matusali G, Pinnetti C, Meschi S, et al.; INMI Monkeypox Study Group. Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding. *Lancet Infect Dis.* 2022;22:1267–9. [https://doi.org/10.1016/S1473-3099\(22\)00513-8](https://doi.org/10.1016/S1473-3099(22)00513-8)
  9. Centers for Disease Control and Prevention. Ocular monkeypox – United States, July–September 2022. 2022 [cited 2022 Dec 15]. <https://www.cdc.gov/mmwr/volumes/71/wr/mm7142e1.htm>

Address for correspondence: Gerami D. Seitzman, University of California San Francisco—Ophthalmology, 490 Illinois St, San Francisco, CA 94158, USA; email: [gerami.seitzman@ucsf.edu](mailto:gerami.seitzman@ucsf.edu)

## National Surveillance of Pediatric Acute Hepatitis of Unknown Etiology, Japan, October 2021–December 2022

Shogo Otake, Chiaki Ikenoue, Natsu Sudani, Miho Kobayashi, Kensuke Takahashi, Tomoe Shimada, Itsuro Yoshimi, Tomoya Saito, Tomimasa Sunagawa

Author affiliations: Kobe University Graduate School of Medicine, Kobe, Japan (S. Otake); National Institute of Infectious Diseases, Tokyo, Japan (S. Otake, C. Ikenoue, N. Sudani, M. Kobayashi, K. Takahashi, T. Shimada, I. Yoshimi, T. Saito, T. Sunagawa)

DOI: <https://doi.org/10.3201/eid2906.221579>

Pediatric acute hepatitis of unknown etiology has been reported globally since April 2022. In Japan, 139 possible cases with onset dates after October 2021 were reported as of December 2022. Three patients required liver transplants, but none died. Rates of adenovirus positivity (11/125, 9%) were lower than those for other countries.

Severe acute hepatitis of unknown etiology (AHUE) in children has been reported globally since April 2022. By July 8, 2022, a total of 1,010 cases had been reported to the World Health Organization from 35 countries on the basis of the working case definitions (1). A definition for a confirmed case is not available, but probable cases are defined as acute hepatitis (non-A–E hepatitis) in persons  $\leq 16$  years of age with serum transaminase  $>500$  IU/L (aspartate transaminase or aspartate aminotransferase) since October 1, 2021; epidemiologically linked cases are acute hepatitis (non-A–E hepatitis) in persons of any age who were close contacts with a probable case–patient since October 1, 2021. Of the 1,010 cases identified, 46 (5%) children required liver transplants, and 22 (2%) children died (1). We report pediatric AHUE cases in Japan and compare them with cases in other countries. Because the data for this study were taken from an epidemiologic investigation conducted by the government, the National Institute of Infectious Diseases did not require informed consent and ethical review (receipt no. 1442).

The Ministry of Health, Labor and Welfare (MHLW) of Japan issued the working case definitions of AHUE on April 27, 2022 (2), adopting the case definition published by the World Health Organization but limiting cases to hospitalized patients (Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/29/6/22-1579-App1.pdf>). Physicians were instructed to exclude viral hepatitis A, B, C, and E through laboratory tests and report cases to public health centers. Laboratories at hospitals and local public health institutions performed microbiological testing recommended by MHLW (Appendix Table 2). Acute liver failure was considered a coagulopathy characterized by a prothrombin time and international normalized ratio of  $\geq 2$  or  $\geq 1.5$  with clinical encephalopathy (3).

As of December 31, 2022, a total of 139 probable AHUE cases with onset dates after October 1, 2021, had been reported throughout Japan without geographic clustering (Table). Six cases with unknown onset dates were excluded, and none were epidemiologically linked. Among the 139 patients, 3 (2%) underwent liver transplantation. Eleven (13%) of 85 patients met the definition of acute liver failure, 17 (18%) of 95 received intensive care, and none died (Table 1).

Of note, of 125 cases tested for adenovirus by PCR, 11 (9%) were positive (Appendix Table 3); however, adenoviruses were the most frequently detected pathogen in AHUE cases from Europe (52%) and the United Kingdom (66%) (4,5). Among the 11 adenovirus-positive cases, type 41 was identified in only 2 cases (18%) in Japan, unlike its frequent detection in England (5) (Appendix Table 1). Studies from the United Kingdom reported simultaneous increases in numbers of hospitalized hepatitis case-patients and detected adenoviruses

cases (5). In Japan, the national surveillance system for viral hepatitis (Appendix Table 4), adenovirus, and adenovirus-associated syndromes (e.g., pharyngoconjunctival fever) did not identify unusual numbers or trends compared with previous years (2). The varying characteristics of reported AHUE cases among countries might be attributed to these differences.

Some reports have stated that SARS-CoV-2 spike protein acts as a superantigen, broadly stimulating T cells to induce hyperinflammation and

**Table 1.** Characteristics and laboratory findings of 139 cases that fulfilled the working case definition of pediatric acute hepatitis of unknown etiology, Japan, October 2021–December 2022\*

Characteristic	Value
Median age, y (IQR)	4.4 (1.3–9.5)
<6 y of age	81/139 (58)
Sex	
M	74/139 (53)
F	65/139 (47)
Any comorbidities†	37/139 (26)
No comorbidities	98/139 (71)
Presence of comorbidities unknown	4/139 (3)
History of COVID-19 before onset of disease	15/132 (11)
Median duration from COVID-19 onset to hepatitis onset, d (range)	85 (14–300)
Persons ≥5 y who received ≥1 dose of COVID-19 vaccine	22/66 (33)
Any international travel in 2 mo before illness	0/130 (0)
Any contact with sick persons in 2 wk before illness	39/129 (30)
Treatment	
Steroid therapy	15/139 (11)
Immunoglobulin	6/139 (4)
Plasmapheresis	6/139 (4)
Hemodialysis	4/139 (3)
Liver transplantation	3/139 (2)
Outcome	
Acute liver failure	11/85 (13)‡
Hospitalized to ICU or HCU	17/95 (18)
Death	0/139 (0)
Median duration from symptom onset to hospital admission, d (IQR)	4 (2–7.5)
Median length of hospital stay, d (IQR)	10 (7–16)
Clinical symptoms§	
Fever 37.5°C or higher	89/138 (64)
Gastrointestinal symptoms: abdominal pain, diarrhea, or nausea/vomiting	75/138 (54)
Cough	29/138 (21)
Jaundice	29/138 (21)
White stools	10/138 (7)
Impaired consciousness	6/138 (4)
Median AST, IU/L (IQR)¶	764 (503–1,312)
Median ALT, IU/L (IQR)¶	838 (576–1,390)
Median total bilirubin, mg/dL (IQR)¶	1.00 (0.60–4.74)
Median PT-INR (IQR)¶	1.11 (1.02–1.32)
No. SARS-CoV-2 positive/no. tested (%)	10/134 (7)
Nucleic acid amplification test: PCR 101, LAMP 1, and NEAR 1	8/103 (8)
Antigen test	2/13 (15)
Type of test unknown	0/18 (0)


\*Values are no. (%) except as indicated. Denominators consist of cases for which data are available. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCU, high-care unit; ICU, intensive care unit; IQR, interquartile range; LAMP, loop-mediated isothermal amplification; NEAR, nicking enzyme amplification reaction; PT-INR, prothrombin time and international normalized ratio.

†Specific underlying conditions reported were psychomotor retardation (11, 8%), syndromes involving changes in chromosomes or genes (5, 4%), congenital heart disease (4, 3%), congenital metabolic disorder (3, 2%), low birthweight (3, 2%), endocrine disorder (3, 2%), autoimmune and collagen diseases (3, 2%), primary immunodeficiency syndrome (2, 1%), and other disorders (8, 6%) (atopic dermatitis, cloacal extrophy, hydronephrosis, unilateral kidney agenesis and haemangioma).

‡Including 3 patients with encephalopathy.

§Some patients reported ≥1 sign/symptom.

¶Maximum values up to the time of reporting. Based on information from 136 (AST and ALT), 99 (total bilirubin), and 85 (PT-INR) cases.



**Figure.** Cases of acute hepatitis of unknown etiology by week of onset in Japan, October 2021–December 31, 2022. The Ministry of Health, Labour, and Welfare Japan issued the working case definitions and administrative notice on April 27, 2022. In total, 139 probable cases with onset dates after October 1, 2021 (week 39, 2021), were reported as of December 31, 2022 (week 52, 2022). We excluded 6 cases for which onset dates were unavailable. Red outlines indicate cases fulfilling the diagnostic criteria for acute liver failure ( $n = 11$ ).

potentially contributing to hepatitis (6). AHUE cases in Europe and United Kingdom revealed high rates of SARS-CoV-2 seropositivity (4,5) (Appendix Table 1). However, our study indicated low SARS-CoV-2 positivity (10/134, 7%) at the time of hospitalization for AHUE in Japan. Results of serologic tests for SARS-CoV-2 were unavailable because they were not required. The low proportion of patients with a history of COVID-19 before onset of AHUE (15/132, 11%) might explain the lower rates of seropositivity in Japan than for Europe and the United Kingdom.

Laboratory tests did not reveal a high frequency of any specific microorganism in Japan, and the distribution, other than for adenovirus, was similar to that reported in Europe (4). The cause of AHUE in Japan remains unknown. Cases reported in Japan were less severe than those reported in other countries (1,2,4,5,7) (Appendix Table 1), which might be because of differences in genetic predisposition that could affect inflammatory responses and clinical severity, as has been suggested with certain acute inflammatory diseases (8). The prevalence of the HLA-DRB1\*04:01 allele, expressed by 89% of AHUE liver transplant cases in Scotland (5), is higher in the general population in Scotland than in Japan (8.9% vs. 1.0%) (9).

The first limitation of our study is that ascertainment bias might have affected microbiological testing results. The pathogens listed by MHLW (Appendix Table 2) might not have been examined uniformly and systematically, and the frequency of pathogens indicated in this report might not accurately reflect actual distribution. Second, the increase in reports after MHLW issued an administrative notice could be caused by reporting bias (Figure). Last, recall bias could have resulted in

underestimates of the number of AHUE cases early in the study period.

In conclusion, we identified 139 pediatric AHUE cases in Japan during October 2021–December 2022 that differed in severity and adenovirus PCR positivity from cases in other countries. However, no unusual trends were found in this investigation. Japan might observe similar AHUE trends as in past years, as in the United States (10).

#### Acknowledgments

We thank the attending physicians, authorized staff at local public health centers, and members of the Ministry of Health, Labour and Welfare (Taito Kitano, Shouhei Nagae, Shuugo Sasaki, Jun Sugihara, and Mayumi Ueda) involved in data collections and case investigations. We thank the staff of Unit 4, Center for Surveillance, Immunization, and Epidemiologic Research, for contributing complementary surveillance information from the National Epidemiological Surveillance of Infectious Diseases system. We also acknowledge the work of the Prefectural and Municipal Public Health Institutes in Japan involved in microbiological testing. In addition, we thank Editage (<http://www.editage.com>) for editing and reviewing our manuscript for English publication.

This study was performed as a part of a grant funded by the Ministry of Health, Labour and Welfare (Research project on global disease intelligence and readiness for emerging diseases, 22HA2002).

#### About the Author

Dr. Otake is a researcher in field epidemiology and a pediatric infectious disease specialist at the National Institute of Infectious Diseases, Tokyo, Japan. His research interests are field epidemiology and pediatric infectious diseases.

## References

1. World Health Organization. Severe acute hepatitis of unknown etiology in children—multi-country. 2022 Jul 12 [cited 2022 Oct 15]. <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON400>
2. National Institute of Infectious Diseases. Acute hepatitis of unknown etiology in children in Japan, October 2021–June 2022, as at Jun 23, 2022 (First report). 2022 Jul 27 [cited 2022 Oct 15]. <https://www.niid.go.jp/niid/en/all-surveillance/2603-fetp/jissekijpn/11344-acute-hepatitis-of-unknown-etiology-in-children-in-japan-october-2021-june-2022-as-at-23-june-2022-first-report.html>
3. Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. *J Pediatr*. 2006;148:652–8. <https://doi.org/10.1016/j.jpeds.2005.12.051>
4. European Centre for Disease Prevention and Control. Joint ECDC-WHO regional office for Europe hepatitis of unknown origin in children surveillance bulletin. 2022 Nov 25 [cited 2022 Dec 31]. <https://www.ecdc.europa.eu/en/hepatitis/joint-hepatitis-unknown-origin-children-surveillance-bulletin>
5. UK Health Security Agency. Investigation into acute hepatitis of unknown etiology in children in England. Technical briefing 4. 2022 Jul 26 [cited 2022 Oct 15]. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1094573/acute-hepatitis-technical-briefing-4.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1094573/acute-hepatitis-technical-briefing-4.pdf)
6. Brodin P, Ardit M. Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens. *Lancet Gastroenterol Hepatol*. 2022;7:594–5. [https://doi.org/10.1016/S2468-1253\(22\)00166-2](https://doi.org/10.1016/S2468-1253(22)00166-2)
7. Cates J, Baker JM, Almendares O, Kambhampati AK, Burke RM, Balachandran N, et al.; Hepatitis of Unknown Etiology Group. Interim analysis of acute hepatitis of unknown etiology in children aged <10 years—United States, October 2021–June 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71:852–8. <https://doi.org/10.15585/mmwr.mm7126e1>
8. Randolph HE, Fiege JK, Thielen BK, Mickelson CK, Shiratori M, Barroso-Batista J, et al. Genetic ancestry effects on the response to viral infection are pervasive but cell type specific. *Science*. 2021;374:1127–33. <https://doi.org/10.1126/science.abg0928>
9. Ikeda N, Kojima H, Nishikawa M, Hayashi K, Futagami T, Tsujino T, et al. Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. *Tissue Antigens*. 2015;85:252–9. <https://doi.org/10.1111/tan.12536>
10. Kambhampati AK, Burke RM, Dietz S, Sheppard M, Almendares O, Baker JM, et al. Trends in acute hepatitis of unspecified etiology and adenovirus stool testing results in children—United States, 2017–2022. *MMWR Morb Mortal Wkly Rep*. 2022;71:797–802. <https://doi.org/10.15585/mmwr.mm7124e1>

Address for correspondence: Tomoe Shimada, Center for Field Epidemic Intelligence, Research and Professional Development, National Institute of Infectious Diseases, J1601 Iidabashi Plano Stage Bldg, 2-7-2 Fujimi, Chiyoda-ku, Tokyo 102-0071, Japan; email: [tomoesh@niid.go.jp](mailto:tomoesh@niid.go.jp)

# etymologia revisited


## Norovirus

[nor'-o-vi'rəs]

Genus of viruses that cause viral gastroenteritis. Noroviruses are named after the original strain, “Norwalk virus,” which caused an outbreak of acute gastroenteritis among children at an elementary school in Norwalk, Ohio, in 1968. Numerous outbreaks of disease with similar symptoms have been reported since, and the etiologic agents were called “Norwalk-like viruses” or “small round-structured viruses.” Noroviruses are transmitted primarily through the fecal-oral route and are highly contagious; as few as 10 viral particles may infect a person.

### Reference:

1. Mahy BWJ. A dictionary of virology. London: Academic Press; 2001; [www.cdc.gov/ncidod/dvrd/revb/gastro/norovirus-qa.htm](http://www.cdc.gov/ncidod/dvrd/revb/gastro/norovirus-qa.htm); [www.medicinenet.com/norovirus\\_infection/article.htm](http://www.medicinenet.com/norovirus_infection/article.htm)



Originally published  
in March 2007

[https://wwwnc.cdc.gov/eid/article/13/3/e1-1303\\_article](https://wwwnc.cdc.gov/eid/article/13/3/e1-1303_article)



Article DOI: <https://doi.org/10.3201/eid2906.221579>

*EID cannot ensure accessibility for supplementary materials supplied by authors.*

*Readers who have difficulty accessing supplementary content should contact the authors for assistance.*

# National Surveillance of Pediatric Acute Hepatitis of Unknown Etiology, Japan, October 2021–December 2022

## Appendix

**Appendix Table 1.** Case definition and characteristics of pediatric acute hepatitis of unknown etiology in each country/region

Country/Region	Japan (2)	EU/EEA (3)	U.S. (4)	UK (5)
Probable case definition published by WHO (1)	Person presenting with acute hepatitis (non-hepatitis A-E) with serum transaminase >500 IU/L (AST or ALT) who is 16 y old or younger, since 1 October 2021			
Differences from WHO probable case definition	Probable case includes only hospitalized cases and excludes acute hepatitis with identifiable cause.	Probable case excludes cases of hepatitis with known etiology such those due to specific infectious diseases, drug toxicity, metabolic hereditary, or autoimmune disorders.	<10 y old	<ul style="list-style-type: none"> <li>• 15 y old or younger (0–10 y: confirmed case, 11–15 y: possible case)</li> <li>• Excluding metabolic, inherited, or genetic, congenital, or mechanical cause.</li> <li>• Scotland case definition also exclude cases due to cytomegalovirus, or Epstein-Barr Virus.</li> </ul>
Investigation period	October 1, 2021-December 31, 2022	October 1, 2021-November 24, 2022	October 1, 2021-June 15, 2022	January 1, 2022-July 4, 2022
Number of reported cases	139 (Probable cases)	572 (Probable cases)	296	274 (Confirmed: 263, Possible: 11)
Acute liver failure	13% (11/85)	-	30% (37/123)	-

Probable case definition published by WHO (1)	Person presenting with acute hepatitis (non-hepatitis A-E) with serum transaminase >500 IU/L (AST or ALT) who is 16 y old or younger, since 1 October 2021			
Hospitalized to ICU or HCU	18% (17/95)	27% (100/371)	-	-
Liver transplantation	2% (3/139)	8% (24/320)	6% (18/296)	5% (15/274)
Death	0% (0/139)	2% (7/405)	4% (11/296)	0% (0/274)
Adenovirus test positivity	9% (11/125)	52% (236/457)	45% (100/224)	66% (170/258)
Type 41	18% (2/11)	42% (5/12)	46% (6/13)	92% (48/52)*
SARS-CoV-2 test positivity	7% (10/134)	10% (40/392)	10% (10/98)	15% (36/237)
SARS-CoV-2 serology test positivity	-	64% (73/115)	-	61% (1- to 4-y-olds), 67% (5- to 10-y-olds) †

ALT, alanine aminotransferase; AST, aspartate aminotransferase; EU/EEA, European Union and European Economic Area; HCU, high care unit; ICU, intensive care unit; UK, United Kingdom; U.S., United States; WHO, World Health Organization

\* Data in England

† The details of the numerator and denominator are unknown.

**Appendix Table 2.** Recommended testing lists in medical institution and local public health institutions by the Ministry of Health, Labor and Welfare

Testing recommendations	
For medical institution	
Virus	Recommended
HAV	Anti-HAV antibody (IgM)
HBV	Hepatitis B surface antigen, anti-HBc antibody
HCV	Anti-HCV antibody
HEV	Anti-HEV antibody (IgA or IgM)
CMV	Anti -CMV antibody (IgM), CMV antigen, CMV PCR test
EBV	Anti-VCA antibody (IgM or IgG), EBV-nuclear antigen antibody
HSV	HSV-1,2 PCR test
SARS-CoV-2	SARS-CoV-2 PCR
For local public health institutions	
Test for adenovirus is recommended first and, the type should be determined, if test is positive.	
Type of sample	Recommended test (PCR test or bacterial culture)
Blood	Enterovirus*, Parechovirus†, HSV-1, 2, CMV, VZV, EBV, HHV-6, 7
Stool	Enterovirus*, Sapovirus, Norovirus, Rotavirus, <i>Salmonella</i> spp., <i>Shigella</i> spp., <i>Campylobacter</i> spp., Enteropathogenic <i>Escherichia coli</i>

---

Testing recommendations

---

Respiratory sample Enterovirus\*, Influenza virus, SARS-CoV-2

---

CMV, cytomegalovirus; EBV, Epstein-Barr virus; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HEV, hepatitis E virus; HHV, human herpes virus; HSV, Herpes simplex virus; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; PCR, polymerase chain reaction; VCA, viral capsid antigen; VZV, Varicella zoster virus

\* If positive, the type should be determined.

† Test should be considered according to age.

**Appendix Table 3.** Laboratory findings for 139 cases that fulfilled the working case definition of pediatric acute hepatitis of unknown etiology, Japan, October 2021–December 2022\*

Viruses detected by PCR	No. positive/no. tested (%)					
	Any specimen	Whole blood/plasma	Serum	Respiratory	Stool	Urine
Adenovirus	11/125 (9)†	1/91 (1)	3/93 (3)	6/101 (6)	7/95 (7)	2/56 (4)
Rhinovirus/enterovirus‡	14/86 (16)	0/53 (0)	0/59 (0)	14/71 (20)	3/56 (5)	1/31 (3)
Human herpes virus 6	4/44 (9)	1/29 (3)	2/31 (6)	1/23 (4)	0/17 (0)	0/13 (0)
Human herpes virus 7	4/41 (10)	2/27 (7)	1/31 (3)	2/23 (9)	0/17 (0)	0/13 (0)
Epstein-Barr virus	4/36 (11)	1/23 (4)	0/22 (0)	2/18 (11)	2/13 (15)	0/11 (0)
Norovirus	3/53 (6)	NT	NT	NT	3/53 (6)	NT
Cytomegalovirus	2/42 (5)	2/29 (7)	1/28 (4)	1/19 (5)	1/14 (7)	0/12 (0)
Herpes simplex virus 1	2/51 (4)	0/36 (0)	0/31 (0)	2/20 (10)	0/15 (0)	0/12 (0)
Human parechovirus 3	1/37 (3)	0/28 (0)	0/28 (0)	1/25 (4)	1/27 (4)	0/16 (0)
Human parainfluenza 3	1/49 (2)	0/21 (0)	1/25 (4)	1/44 (2)	0/20 (0)	0/13 (0)
Rotavirus	1/52 (2)	NT	NT	NT	1/52 (2)	NT
Sapovirus	1/49 (2)	NT	NT	NT	1/49 (2)	NT

\*NT, not tested.

†There were 2 cases of type 41 and 1 case each of adenovirus type 1, type 2, type 3, and type 1 and 2, and 5 cases of unknown serotype.

‡Because the PCR tests in some cases could not distinguish between rhinovirus and enterovirus, we integrated them.

**Appendix Table 4.** Notification criteria of viral hepatitis based on the national law (Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases)

Case definition	An acute hepatitis caused by hepatitis A-E virus or other viruses including asymptomatic cases. Chronic liver disease, asymptomatic carriers, and acute-on-chronic liver failure due to hepatitis B and C should be excluded.
Notification criteria	Physicians must notify the prefectural governor if they diagnose viral hepatitis based on clinical symptoms and laboratory findings such as serology test or polymerase chain reaction test, regardless of severity.

## References

1. World Health Organization. Severe acute hepatitis of unknown etiology in children—multi-country. 2022 Jul 12 [cited 2022 Oct 15]. <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON400>
2. National Institute of Infectious Diseases. Acute hepatitis of unknown etiology in children in Japan, October 2021–June 2022, as at Jun 23, 2022 (First report). 2022 Jul 27 [cited 2022 Oct 15]. <https://www.niid.go.jp/niid/en/all-surveillance/2603-fetp/jissekijpn/11344-acute-hepatitis-of-unknown-etiology-in-children-in-japan-october-2021-june-2022-as-at-23-june-2022-first-report.html>
3. European Centre for Disease Prevention and Control. Joint ECDC-WHO regional office for Europe hepatitis of unknown origin in children surveillance bulletin. 2022 Nov 25 [cited 2022 Dec 31]. <https://www.ecdc.europa.eu/en/hepatitis/joint-hepatitis-unknown-origin-children-surveillance-bulletin>
4. Cates J, Baker JM, Almendares O, Kambhampati AK, Burke RM, Balachandran N, et al.; Hepatitis of Unknown Etiology Group. Interim analysis of acute hepatitis of unknown etiology in children aged <10 years—United States, October 2021–June 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:852–8. [PubMed <https://doi.org/10.15585/mmwr.mm7126e1>](https://doi.org/10.15585/mmwr.mm7126e1)



5. UK Health Security Agency. Investigation into acute hepatitis of unknown etiology in children in England. Technical briefing 4. 2022 Jul 26 [cited 2022 Oct 15].

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1094573/acute-hepatitis-technical-briefing-4.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1094573/acute-hepatitis-technical-briefing-4.pdf)